Chris Pasquale

I'd love your thoughts on what's left to penetrate with TSA, particularly as we think about other procedure categories like SBT or VT

Is there enough room just in ISR to sustain the current momentum, especially with competition may be coming into the U.S. next year

You didn't mention China, which I think was a big piece of the weakness last year. So what are you seeing in that market?

you talked about still being on track to do over $100 million from my side this year. I think the original goal for the year was 40% growth. And three quarters in, by our math, you're maybe a littl...

is this downshift in market growth as simple as pricing trends returning to what we used to consider normal?

on MySite, to get to that 40% goal for the year, growth does need to pick up from here. Is MyDay, MySite part of how you get there

are we right in thinking you guys have about $25 million in annualized revenue from the more recent deals

I was hoping you could just comment on the sustainability of the pricing environment you're seeing in contact lenses

You tweaked up the high end of your operating margin and EBITDA ranges a little bit, but those seem conservative given where you are starting and the normal cadence we see throughout the year

I would love it if you could give us an update on where the installed base stands today relative to the more than 140,000 users you had in mid-January

how are you feeling about your ability to keep users engaged after they've through their first couple sensors

I wanted to circle back to the MCD and how that could change things from a practical perspective when it does come. I'm curious what you're seeing so far from the Local MAC

we saw some updated data from the AlignAR trial at ACC. Continues to look solid

I would love to hear how you're thinking about the time line for Hugo to really begin to move the needle within the Surgical business? And any qualitative comments you can make about the system pip...

How much of your current insulin pump installed base maybe in the U.S., that's easier, is made up of Type 2 patients?

now that you've reached the 70% milestone, how much higher do you think you can get gross margin longer term

Clinicaltrials.gov right now has Peerless two wrapping up this year. Is that still accurate? And when should we expect to see your data

You noted that you're now lapping the Pangea launch. I know you guys tend to talk about product rollouts being multiyear affairs

1 of your competitors have been dealing with an issue that impacted their ability to serve customers for a few weeks at the end of the quarter

organic growth for SCT still did step down a bit. Can you talk a little bit about the other SCT segments

the biggest concern about pursuing a fully autonomous capability for ortho robotics was the perceived onerous regulatory requirements to get sign off from the FDA

are those true new to Zimmer surgeons or does that include surgeons who were maybe already customers on the Knees side